On August 10, 2022, the U.S. Food and Drug Administration (FDA) granted regular approval to capmatinib (Tabrecta®) for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation leading to mesenchymal-epithelial transition exon 14 skipping, as detected by an FDA-approved test.
To raise awareness and better educate patients and providers about biosimilars’ potential in clinical care, the U.S. Food and Drug Administration (FDA) added three new fact sheets to its healthcare provider resources in July 2022.
Clinical decision support systems are tools integrated into electronic health records that include reminders for preventive care, evidence-based clinical practice guidelines, order sets, and alerts for drug prescribing. In health care, artificial intelligence converts data into knowledge to guide clinical decisions. When combined, the two technologies can guide advanced practice RNs and other providers with predictions and suggestions that go beyond human accuracy and specificity.
To decrease cost and increase access to care, in July 2022 the Centers for Medicare and Medicaid Services proposed a conversion factor of $33.08 for the 2023 Physician Fee Schedule.
In findings that could have global implications to change the face of female cancers, researchers reported that a single dose of the human papillomavirus (HPV) vaccine is highly effective in protecting young women against cervical infection with cancer-causing HPV types. The study results, which were published in NEJM Evidence, build on the body of evidence supporting single-dose HPV vaccines.
As the most trusted professionals for 20 years in a row, nurses witness the needs of those in our care and are suited to translate them to legislatures, regulatory agencies, nongovernmental organizations, and insurers. We do that by speaking plainly about the impact that cancer has on patients and their families. As experts, our ideas and language can translate into practice changes to transform cancer care.
E-cigarette marketing application reviews won’t conclude until June 2023, the U.S. Food and Drug Administration (FDA) said in a status report in May 2022, sparking frustration among healthcare advocates.
Healthcare professionals are called to provide patient-centered care in an environment where they listen to patients’ goals and desires and support patient autonomy. However, heeding that call requires patients’ participation to voice their needs and concerns, and some patients may be reluctant to speak up for themselves.
Financial considerations are notable barriers for patients with cancer receiving follow-up cancer care, according to study findings from the National Institutes of Health (NIH) All of Us Research Program.
On August 5, 2022, the U.S. Food and Drug Administration (FDA) approved darolutamide (Nubeqa®) tablets in combination with docetaxel for adult patients with metastatic hormone-sensitive prostate cancer.